Search results
Results from the WOW.Com Content Network
Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL). Metabolic syndrome is associated with the risk of developing cardiovascular disease and type 2 diabetes. [1]
A fourth class of dual PPAR agonists, so-called glitazars, which bind to both the α and γ PPAR isoforms, are currently under active investigation for treatment of a larger subset of the symptoms of the metabolic syndrome. [5] [6] These include the experimental compounds aleglitazar, muraglitazar, oxeglitazar, naveglitazar and tesaglitazar.
Antipsychotic drug treatment is a key component of schizophrenia treatment ... Metabolic syndrome and other metabolic problems such as type II ...
Information on the DASH diet, an anti-inflammatory diet is available at Metabolic Syndrome - Treatment | NHLBI, NIHThe components of a similar diet known as the Mediterranean-diet can be accessed ...
Treatment for MASLD is weight loss by dietary changes and exercise; [5] [14] [15] bariatric surgery can improve or resolve severe cases. [14] [16] There is some evidence for SGLT-2 inhibitors, GLP-1 agonists, pioglitazone, and vitamin E in the treatment of MASLD. [17] [18] In March 2024, resmetirom was the first drug approved by the FDA for ...
“GLP-1 medications might help lower COPD exacerbation risk by reducing systemic inflammation, improving metabolic function, and possibly having direct effects on lung tissue,” she continued ...
Blood pressure greater than or equal to 130 mm Hg systolic or 85 mm Hg diastolic, or undergoing drug treatment for hypertension; Approximately 40–46 percent of the world's adult population has the cluster of risk factors that is metabolic syndrome. [5] In 2000, approximately 32% of U.S. adults had the metabolic syndrome. [1]
Leptin replacement therapy with human recombinant leptin metreleptin has been shown to be an effective therapy to alleviate the metabolic complications associated with lipodystrophy, and has been approved by the FDA for the treatment of generalized lipodystrophy syndromes. [14]